Anna R Minchom

20PUBLICATIONS
237CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 28, 2026
Correction: Cruz et al. Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers 2026, 18, 880.

|Jun 08, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.

|Apr 27, 2026
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

|Mar 14, 2026
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer.

Pedro Cruz, Cristina Boixareu, Diogo J Silva

|Jan 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.

Emily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck

|Aug 01, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Jia Liu, Anna R Minchom, Alastair Greystoke

Pageof 4

Frequent Collaborators

5 joint publications

Udai Banerji

5 joint publications

Christina Yap

4 joint publications

Juanita Lopez

3 joint publications

Bora Gurel